Brian Ward, MD
Gastroenterology · Omaha, NENPI 1366494643
Payments from drug & device makers
Across 471 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$1K
- Gilead$908
- Takeda Pharmaceuticals U.S.A., Inc.$729
- Aimmune Therapeutics, Inc.$679
- Sanofi$590
- plus $3K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 75 | $1,117 |
| Johnson & Johnson(2 entities) | 78 | $1,019 |
| Gilead | 44 | $908 |
| Takeda Pharmaceuticals U.S.A., Inc. | 43 | $729 |
| Aimmune Therapeutics, Inc. | 5 | $679 |
| Sanofi | 28 | $590 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 34 | $531 |
| QOL Medical, LLC | 26 | $461 |
| Madrigal Pharmaceuticals | 20 | $333 |
| Regeneron Healthcare Solutions, Inc. | 11 | $222 |
| Pfizer | 18 | $209 |
| Bristol Myers Squibb | 14 | $196 |
| Ironwood Pharmaceuticals, Inc | 9 | $166 |
| Ardelyx, Inc. | 8 | $141 |
| Lilly USA, LLC | 6 | $138 |
| Phathom Pharmaceuticals, Inc. | 14 | $120 |
| Amgen | 6 | $117 |
| Intercept Pharmaceuticals, Inc. | 6 | $90 |
| Ferring Pharmaceuticals Inc. | 6 | $87 |
| Merck | 5 | $76 |
| Ipsen Biopharmaceuticals, Inc | 2 | $46 |
| Celltrion USA Inc. | 2 | $36 |
| Organon | 3 | $35 |
| Nestle Healthcare Nutrition Inc. | 2 | $29 |
| Covidien LP | 1 | $23 |
| Welch Allyn | 1 | $17 |
| Novo Nordisk | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Baxter Healthcare | 1 | $13 |
| UCB, Inc. | 1 | $12 |
How this compares
$8,172 in reported general payments places this provider in the 75th percentile of 89 gastroenterology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Omaha
- Sandeep MukherjeeOmaha$449K
- John FerryOmaha$177K
- Wuttiporn ManatsathitOmaha$174K
- Benjamin HallOmaha$154K
- Alexander HewlettOmaha$150K
- Derrick EicheleOmaha$141K
- Helen Fasanya-UptagraftOmaha$141K
- Rowen ZettermanOmaha$119K
- Robert KizerOmaha$84K
- Peter MannonOmaha$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.